Symptoms/Treatment: Excessive anticoagulation, with or without bleeding, may be controlled by discontinuing Argatroban or by decreasing the Argatroban infusion dosage (see WARNINGS). In clinical studies at therapeutic levels, anticoagulation parameters generally return to baseline within 2 to 4 hours after discontinuation of the drug. Reversal of anticoagulant effect may take longer in patients with hepatic impairment.

No specific antidote to Argatroban is available; if life-threatening bleeding occurs and excessive plasma levels of Argatroban are suspected, Argatroban should be discontinued immediately, aPTT and other coagulation tests should be determined. Symptomatic and supportive therapy should be provided to the patient (see WARNINGS). When Argatroban was administered as a continuous infusion (2 mcg/kg/min) prior to and during a 4-hour hemodialysis session, approximately 20% of Argatroban was cleared through dialysis.

Single intravenous doses of Argatroban at 200, 124, 150, and 200 mg/kg were lethal to mice, rats, rabbits, and dogs, respectively. The symptoms of acute toxicity were loss of righting reflex, tremors, clonic convulsions, paralysis of hind limbs, and coma.

Argatroban is contraindicated in patients with overt major bleeding, or in patients hypersensitive to this product or any of its components (see WARNINGS).

Bookmark this page: